Board of Directors

Jacob Gunterberg is a former partner at HealthCap and has a background in venture capital investment operations and corporate finance advisory services focusing on the life sciences sector. Jacob Gunterberg has long experience as board member in both private and publicly traded companies.

Shareholdings: View shareholding

Share awards: 24,806

Education: M.Sc. in Business Administration and Economics from Lund University.

Other assignments:Board member in AO Pharma AB, Aurelia Invest AB, Disruptive Pharma Holding AB, EllAug AB, Tova Skrenen Stockholm AB and Twiceme Technology Sweden AB.

Independent of the company and its senior management but dependent of major shareholders of the company.

Heidi Hunter has more than 25 years of experience from leading positions in different roles within pharmaceutical development and commercialization. She has worked strategically and operationally from clinical and commercial development to launch execution.  Her leadership experience spans alliance management, investment risk mitigation, global clinical and commercial management, new business strategy development, product launch, and business sustainability. Heidi has a unique, multicultural and global experience of engaging people from different cultures to work towards the same vision and goals.

Holdings in Vicore: View shareholding

Share awards: 11,025

Education: M.B.A., Marketing and International Business, The University of Chicago. B.A., Economics and German, Magna cum laude, The University of Michigan

Other assignments: Board member Sutro Biopharma, advisory board member MiGenTra

Independent of the company and its senior management and independent of major shareholders of the company.

Maarten Kraan has extensive experience in biomedicine and has, among others, held a senior positions at Schering Plough, Bristol Myers Squibb, Roche/Genentech and AstraZeneca AB where he was responsible for the research and development of medicines for respiratory, inflammatory and autoimmune symptoms.

Shareholdings: View shareholding

Share awards: 31,616

Education: Doctor’s degree in rheumatology at the University of Leiden.

Other assignments:CMO at AM-Pharma. Maarten Kraan is a board member of Toleranzia AB and CDS Gmbh. Scientific advisor for AER therapeutics and Cyxone AB.

Independent of the company and its senior management and independent of major shareholders of the company.

Hans Schikan is former CEO of Prosensa (acquired by BioMarin). His previous assignments include leadership roles at Genzyme (acquired by Sanofi) and Organon. He served on the boards of Hansa Biopharma, Wilson Therapeutics (acquired by Alexion), Swedish Orphan Biovitrum, Asceneuron, InteRNA and Therachon (acquired by Pfizer).

Shareholdings: View shareholding

Share awards: 31,616

Education: Pharmacist degree (PharmD) from the University of Utrecht.

Other assignments:Chairman of Microbiotica Ltd and Complix NV. Board member of VectivBio AG, Pharvaris NV and the Dutch Top Sector Life Sciences & Health. Advisor to various organisations in Life Sciences & Health.

Independent of the company and its senior management and independent of major shareholders of the company.

Elisabeth Björk is SVP, Late-Stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D at AstraZeneca, where she oversees clinical development from phase I-IV, large outcomes programs, major global filings and regulatory interactions, as well as global commercial strategy and implementation across regions and therapy areas. Prior to joining AstraZeneca in 2002, Dr Björk spent over 15 years in clinical practice and academic research.

Shareholdings: View shareholding

Share awards: 11,025

Education: MD, Karolinska Institute and Ph.D. in Endocrinology, Uppsala University.

Other assignments: SVP, Head of late phase CVRM BioPharmaceutical R&D, AstraZeneca Site lead in Gothenburg. Board member of Calliditas Therapeutics AB, Pharvaris N.V., Agiana Pharma AS, Rocket Pharmaceuticals, Inc. and Chalmers University of Technology. Dr. Björk also serves on the Swedish Government’s strategic innovation partnership program for life science.

Independent of the company and its senior management and independent of major shareholders of the company.

Michael Buschle has more than 25 years’ experience in basic research as well as from biotech and pharma R&D. Dr Buschle has held C-level positions at mid-size Pharma and biotech companies. Among others, Dr Buschle was a co-founder of vaccine company Intercell AG (merged with Vivalis to create Valneva in 2012) and President Biologics and Chief Scientific Officer at Glenmark Pharmaceuticals.

Shareholdings: View shareholding

Share awards: 11,025

Education: Ph.D. from the University of London

Other assignments: Consultant of HBM Partners AG.

Independent of the company and its senior management and independent of major shareholders of the company.